Tech Company Financing Transactions
Spirea Limited Funding Round
On 6/14/2022, Spirea Limited raised $2.9 million in funding from Cambridge Enterprise, private investors and ACF Investors.
Transaction Overview
Company Name
Announced On
6/14/2022
Transaction Type
Venture Equity
Amount
$2,900,000
Round
Undisclosed
Investors
Cambridge Enterprise (Lead Investor)
private investors (Lead Investor) (Jonathan Milner)
Proceeds Purpose
The company will use the funds to initiate its pipeline of differentiated ADCs in the treatment of solid tumours. ADCs combine the cell killing activity of a cytotoxic drug with the cancer targeting capability of a monoclonal antibody.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Windsor House Cornwall Road
Harrogate England, HG1 2PW
UK
Harrogate England, HG1 2PW
UK
Phone
Undisclosed
Website
Email Address
Overview
Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jane Dancer
Chief Executive Officer
Myriam Ouberai
Browse more venture capital transactions:
Prev: 6/14/2022: The Wildcard Alliance venture capital transaction
Next: 6/14/2022: KEO World venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs